Janssen Boosts Multiple Myeloma R&D With Genmab Deal
This article was originally published in The Pink Sheet Daily
Janssen Biotech has signed its second deal in less than two months with antibody discovery company Genmab, this time licensing the Danish company's potential first-in-class multiple myeloma therapy daratumumab for $55 million upfront and an equity investment.
You may also be interested in...
Speedy even by the standards of accelerated approval, FDA’s clearance of first-in-class daratumumab in salvage setting gives hope for broader ambitions in myeloma and beyond.
MorphoSys is putting on a brave face after Celgene handed back rights to its anti-CD38 monoclonal antibody MOR202, saying it will carry on with current trials in multiple myeloma patients and voicing confidence it can find another commercial partner “once the time is right.”
Genmab has made progress with partnered lead antibodies ofatumumab and daratumumab in frontline CLL and refractory multiple myeloma respectively, while also boosting its financial guidance and cash balance.